Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through

RNA interference RNA interference (RNAi) is a biological process in which RNA molecules are involved in sequence-specific suppression of gene expression by double-stranded RNA, through translational or transcriptional repression. Historically, RNAi was known by ...

(RNAi) mechanisms of action. The company focuses on treatments for

hepatitis B Hepatitis B is an infectious disease caused by the '' hepatitis B virus'' (HBV) that affects the liver; it is a type of viral hepatitis. It can cause both acute and chronic infection. Many people have no symptoms during an initial infection. ...

, liver disease associated with

alpha 1-antitrypsin deficiency Alpha-1 antitrypsin deficiency (A1AD or AATD) is a genetic disorder that may result in lung disease or liver disease. Onset of lung problems is typically between 20 and 50 years of age. This may result in shortness of breath, wheezing, or an inc ...

and

cardiovascular disease Cardiovascular disease (CVD) is any disease involving the heart or blood vessels. CVDs constitute a class of diseases that includes: coronary artery diseases (e.g. angina, heart attack), heart failure, hypertensive heart disease, rheumati ...

History

In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full

RNAi RNA interference (RNAi) is a biological process in which RNA molecules are involved in sequence-specific suppression of gene expression by double-stranded RNA, through translational or transcriptional repression. Historically, RNAi was known b ...

research and development portfolio, and assets from

Novartis Novartis AG is a Swiss multinational corporation, multinational pharmaceutical company, pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by re ...

. In April 2016, the company announced a name change from Arrowhead Research Corporation to Arrowhead Pharmaceuticals, Inc. In September 2016, Arrowhead entered into two collaboration and licensing agreements with

Amgen Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical Corporation, company headquartered in Thousand Oaks, California. As one of the world's largest independent biotechnology companies, Amgen has a ...

. Under the deals,

received a worldwide exclusive license to Arrowhead’s ARO-LPA

program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease. On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. As part of the deal, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three more RNA interference (RNAi) therapeutics against new targets to be selected by Janssen.

Products

The company has sixteen products in its pipeline, in various stages of development.

References

External links

* {{Finance links , name = Arrowhead Pharmaceuticals, Inc. , symbol = ARWR , sec_cik = 879407 , yahoo = ARWR , google = ARWR:NASDAQ Pharmaceutical companies of the United States Companies listed on the Nasdaq